Rosalind Eeles

Q: What Schools Are Affiliated With Rosalind Eeles

Rosalind Eeles is affiliated with the following schools: University of Cambridge, Medical University of Vienna, Institute of Cancer Research, University of Melbourne

Rosalind Eeles's AcademicInfluence.com Rankings

Rosalind Eeles

Biology

#6449

World Rank

#9167

Historical Rank

Genetics

#599

World Rank

#681

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Rosalind Eeles Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Rosalind Anne Eeles is a Professor of Oncogenetics at the Institute of Cancer Research and clinician at the Royal Marsden NHS Foundation Trust. She is a leader in the field of genetic susceptibility to prostate cancer, and is known for the discovery of 14 genetic variants involved in prostate cancer predisposition. According to ResearchGate, Eeles has published more than 500 articles in peer-reviewed journals, with over 34,000 citations and an h-index of 92. Eeles was elected a Fellow of the Academy of Medical Science in 2012. She was awarded a National Institute for Health Research Senior Investigator Emeritus in 2014.

(See a Problem?)

Rosalind Eeles's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Identification of the breast cancer susceptibility gene BRCA2 (1995) (2451)
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. (2015) (1670)
Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers (2017) (1644)
Identification of the breast cancer susceptibility gene BRCA2 (1996) (1451)
The IARC TP53 database: New online mutation analysis and recommendations to users (2002) (1279)
The Evolutionary History of Lethal Metastatic Prostate Cancer (2015) (1150)
REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. (2016) (1110)
Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS) (2005) (1061)
Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. (2016) (1060)
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. (2010) (1008)
Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial (1998) (921)
Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus (1994) (912)
Multiple newly identified loci associated with prostate cancer susceptibility (2008) (866)
Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations (2002) (860)
Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. (2013) (802)
Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. (1998) (661)
Localization of the gene for Cowden disease to chromosome 10q22–23 (1996) (641)
Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. (2013) (619)
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array (2012) (550)
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. (2012) (544)
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. (2008) (527)
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci (2018) (509)
Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. (2003) (474)
Stereotactic body radiotherapy for oligometastases. (2013) (453)
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. (2018) (452)
CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. (2004) (442)
Identification of seven new prostate cancer susceptibility loci through a genome-wide association study (2009) (428)
A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer (2014) (416)
Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. (2005) (412)
Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk (2013) (405)
Spatial genomic heterogeneity within localized, multifocal prostate cancer (2015) (401)
Analysis of the Genetic Phylogeny of Multifocal Prostate Cancer Identifies Multiple Independent Clonal Expansions in Neoplastic and Morphologically Normal Prostate Tissue (2015) (399)
Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. (2015) (390)
"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. (2008) (385)
Patterns of somatic structural variation in human cancer genomes (2020) (377)
Influence of cytokine gene polymorphisms on the development of prostate cancer. (2002) (373)
Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. (2003) (365)
Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer (2014) (358)
Prevention and early detection of prostate cancer. (2014) (357)
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general population (2010) (357)
Multiple loci with different cancer specificities within the 8q24 gene desert. (2008) (357)
Genome-wide association studies in cancer. (2008) (352)
BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients (2011) (337)
Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. (2006) (328)
Multiple loci on 8q24 associated with prostate cancer susceptibility (2009) (316)
Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study (2017) (302)
Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study (2011) (295)
Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes (2014) (289)
Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. (2014) (288)
Prostate cancer (2016) (288)
Germline mutations in the TP53 gene. (1995) (277)
Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. (2015) (276)
Prostate cancer patients' support and psychological care needs: Survey from a non‐surgical oncology clinic (2003) (273)
Germline BRCA1 mutations increase prostate cancer risk (2012) (273)
Diversity of TMPRSS2-ERG fusion transcripts in the human prostate (2007) (270)
Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. (2008) (270)
The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers (2016) (267)
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. (2020) (260)
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 (2015) (256)
Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study (2018) (256)
The impact of genetic counselling on risk perception and mental health in women with a family history of breast cancer (1999) (251)
Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer (2017) (244)
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. (2008) (238)
A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome (1992) (233)
Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects (2005) (233)
The genetic epidemiology of prostate cancer and its clinical implications (2014) (232)
Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study (2014) (222)
Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK) (2012) (214)
Familial breast cancer: a controlled study of risk perception, psychological morbidity and health beliefs in women attending for genetic counselling. (1996) (214)
Global Patterns of Prostate Cancer Incidence, Aggressiveness, and Mortality in Men of African Descent (2013) (212)
Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers (2017) (211)
Mutational signatures of ionizing radiation in second malignancies (2016) (207)
Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations (2018) (206)
Li-Fraumeni syndrome: cancer risk assessment and clinical management (2014) (203)
Balancing autonomy and responsibility: the ethics of generating and disclosing genetic information (2003) (201)
Comprehensive molecular characterization of mitochondrial genomes in human cancers (2017) (197)
Psychosocial impact of breast/ovarian (BRCA1/2) cancer-predictive genetic testing in a UK multi-centre clinical cohort (2004) (192)
Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome (2004) (188)
Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics (2008) (186)
HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG) (2012) (186)
Genome-wide association study identifies new prostate cancer susceptibility loci. (2011) (183)
Head and neck sarcomas: prognostic factors and implications for treatment. (1993) (180)
PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS (2016) (174)
Interplay between BRCA1 and RHAMM Regulates Epithelial Apicobasal Polarization and May Influence Risk of Breast Cancer (2011) (174)
Multiple Novel Prostate Cancer Predisposition Loci Confirmed by an International Study: The PRACTICAL Consortium (2008) (169)
Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets (2018) (169)
Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. (2016) (168)
Comprehensive Functional Annotation of 77 Prostate Cancer Risk Loci (2014) (168)
Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction (2021) (163)
The role of BRCA1 and BRCA2 in prostate cancer. (2012) (163)
A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. (2005) (161)
Complex patterns of ETS gene alteration arise during cancer development in the human prostate (2008) (160)
Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype (2008) (159)
Androgen receptor polymorphisms: Association with prostate cancer risk, relapse and overall survival (1999) (158)
Germline PTEN mutations in Cowden syndrome-like families. (1998) (157)
Polygenic susceptibility to prostate and breast cancer: implications for personalised screening (2011) (155)
Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer (2010) (154)
Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. (2007) (151)
Family history of breast cancer: what do women understand and recall about their genetic risk? (1998) (151)
Identification of nine new susceptibility loci for testicular cancer, including variants near DAZL and PRDM14 (2013) (149)
Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. (2016) (146)
Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC) (2007) (145)
Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts (2018) (144)
Reproductive and Hormonal Factors, and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers: Results from the International BRCA1/2 Carrier Cohort Study (2009) (143)
Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores (2017) (142)
Hormone replacement therapy and survival after surgery for ovarian cancer. (1991) (140)
Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis (2017) (139)
Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers. (2006) (138)
Heterogeneous Genetic Background of the Association of Pheochromocytoma/Paraganglioma and Pituitary Adenoma: Results From a Large Patient Cohort (2014) (138)
Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis (2010) (133)
Association analyses identify 31 new risk loci for colorectal cancer susceptibility (2019) (132)
The contribution of rare variation to prostate cancer heritability (2015) (132)
The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators. (2000) (131)
A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. (2013) (131)
We are talking, but are they listening? Communication patterns in families with a history of breast/ovarian cancer (HBOC) (2004) (130)
Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers (2019) (129)
Linkage analysis of chromosome 1q markers in 136 prostate cancer families. The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators. (1998) (128)
Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. (1995) (128)
Cost-effectiveness of screening with contrast enhanced magnetic resonance imaging vs X-ray mammography of women at a high familial risk of breast cancer (2006) (127)
Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease (2014) (125)
A genome-wide association scan (GWAS) for mean telomere length within the COGS project: identified loci show little association with hormone-related cancer risk (2013) (125)
Communication about genetic testing in families of male BRCA1/2 carriers and non‐carriers: patterns, priorities and problems (2005) (124)
Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. (2009) (124)
Guilt, blame and responsibility: men's understanding of their role in the transmission of BRCA1/2 mutations within their family. (2006) (119)
Genetic determinants of telomere length and risk of common cancers: a Mendelian randomization study (2015) (119)
Germ-Line Mutations in Mismatch Repair Genes Associated with Prostate Cancer (2009) (113)
Early outcomes of active surveillance for localized prostate cancer (2005) (112)
Detection of point mutations in the p53 gene: Comparison of single‐strand conformation polymorphism, constant denaturant gel electrophoresis, and hydroxylamine and osmium tetroxide techniques (1993) (112)
DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers (2014) (112)
Allelic imbalance, including deletion of PTEN/MMAC1, at the Cowden disease locus on 10q22‐23, in hamartomas from patients with cowden syndrome and germline PTEN mutation (1998) (112)
Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study (2000) (110)
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. (2019) (110)
A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers (2004) (110)
Cowden syndrome and Lhermitte-Duclos disease in a family: a single genetic syndrome with pleiotropy? (1994) (110)
The role of genetic markers in the management of prostate cancer. (2012) (108)
Common Breast Cancer Susceptibility Variants in LSP1 and RAD51L1 Are Associated with Mammographic Density Measures that Predict Breast Cancer Risk (2012) (107)
Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study☆ (2020) (106)
Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium (2002) (106)
A Review of Prostate Cancer Genome-Wide Association Studies (GWAS) (2018) (105)
Accommodating risk: responses to BRCA1/2 genetic testing of women who have had cancer. (2004) (105)
Identification of 19 new risk loci and potential regulatory mechanisms influencing susceptibility to testicular germ cell tumor (2017) (104)
Validation of Genome-Wide Prostate Cancer Associations in Men of African Descent (2010) (104)
Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study (2011) (104)
Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia (2014) (103)
Identification of a novel prostate cancer susceptibility variant in the KLK3 gene transcript (2011) (102)
Association of Folate-Pathway Gene Polymorphisms with the Risk of Prostate Cancer: a Population-Based Nested Case-Control Study, Systematic Review, and Meta-analysis (2009) (102)
Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (2011) (101)
Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression (2013) (100)
Relationship between glutathione S-transferase M1, P1 and T1 polymorphisms and early onset prostate cancer. (2001) (98)
Radiogenomics: radiobiology enters the era of big data and team science. (2014) (96)
A Pilot Study of Compositional Analysis of the Breast and Estimation of Breast Mammographic Density Using Three-Dimensional T1-Weighted Magnetic Resonance Imaging (2008) (94)
Family stories and the use of heuristics: women from suspected hereditary breast and ovarian cancer (HBOC) families. (2003) (93)
Large-scale transcriptome-wide association study identifies new prostate cancer risk regions (2018) (93)
Genetic variants associated with predisposition to prostate cancer and potential clinical implications (2012) (93)
Assessing the usefulness of a novel MRI-based breast density estimation algorithm in a cohort of women at high genetic risk of breast cancer: the UK MARIBS study (2009) (92)
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers (2012) (92)
ATM polymorphisms as risk factors for prostate cancer development (2004) (92)
A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease (2016) (92)
Overexpression of RAD51 occurs in aggressive prostatic cancer (2009) (90)
Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis (2014) (89)
The rs10993994 Risk Allele for Prostate Cancer Results in Clinically Relevant Changes in Microseminoprotein-Beta Expression in Tissue and Urine (2010) (89)
Genetic testing for women previously diagnosed with breast/ovarian cancer: examining the impact of BRCA1 and BRCA2 mutation searching. (2002) (88)
Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations. (2016) (87)
TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer (2008) (87)
Predictive testing for BRCA1/2: attributes, risk perception and management in a multi-centre clinical cohort (2002) (86)
Too much, too soon? Patients and health professionals' views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40. (2005) (86)
A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact (2011) (86)
Screening hCHK2 for mutations. (2000) (86)
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. (2019) (85)
Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2 (2016) (84)
Predictive genetic testing for BRCA1/2 in a UK clinical cohort: three-year follow-up (2007) (84)
Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. (2007) (83)
Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants (2018) (83)
CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers (2001) (82)
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. (2011) (82)
Attitudes to reproductive genetic testing in women who had a positive BRCA test before having children: a qualitative analysis (2011) (81)
Relationship between glutathione S-transferase M1, T1, and P1 polymorphisms and chronic lymphocytic leukemia. (2002) (81)
Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma (2018) (81)
Differences in Natural History between Breast Cancers in BRCA1 and BRCA2 Mutation Carriers and Effects of MRI Screening-MRISC, MARIBS, and Canadian Studies Combined (2012) (79)
Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes. (2015) (79)
The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium (2015) (78)
Molecular markers for predicting prostate cancer stage and survival (2000) (78)
Association Between BRCA 1 and BRCA 2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer (2012) (77)
Hand pattern indicates prostate cancer risk (2010) (76)
Men’s Decision-Making About Predictive BRCA1/2 Testing: The Role of Family (2005) (76)
Limb function following conservation treatment of adult soft tissue sarcoma. (1991) (75)
Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells (2015) (75)
Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes (2019) (74)
CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumours (2002) (72)
Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans (2015) (71)
Living with chronic risk: healthy women with a family history of breast/ovarian cancer (2003) (70)
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer (2017) (70)
Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline 'de-novo' TP53 mutation. (2007) (70)
Genetic predisposition to prostate cancer. (2016) (69)
Cancers in BRCA1 and BRCA2 carriers and in women at high risk for breast cancer: MR imaging and mammographic features. (2009) (69)
Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial. (2015) (68)
Unravelling the genetics of prostate cancer (2004) (68)
Genetic Testing for Breast and Ovarian Cancer Predisposition: Cancer Burden and Responsibility (2002) (68)
Juggling roles and expectations: dilemmas faced by women talking to relatives about cancer and genetic testing (2004) (67)
Shared heritability and functional enrichment across six solid cancers (2018) (67)
Constitutional mutation in exon 8 of the p53 gene in a patient with multiple primary tumours: molecular and immunohistochemical findings. (1993) (65)
Reproductive decision-making in young female carriers of a BRCA mutation. (2013) (65)
Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci (2015) (65)
Late Toxicity Is Not Increased in BRCA1/BRCA2 Mutation Carriers Undergoing Breast Radiotherapy in the United Kingdom (2006) (65)
Non-uptake of predictive genetic testing for BRCA1/2 among relatives of known carriers: attributes, cancer worry, and barriers to testing in a multicenter clinical cohort. (2004) (64)
Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers (2010) (63)
Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium (2014) (62)
Association between Adult Height and Risk of Colorectal, Lung, and Prostate Cancer: Results from Meta-analyses of Prospective Studies and Mendelian Randomization Analyses (2016) (62)
Increasing evidence that germline mutations in CHEK2 do not cause Li‐Fraumeni syndrome (2002) (62)
A Multicenter Study of Cancer Incidence in CHEK2 1100delC Mutation Carriers (2006) (61)
Generalizability of established prostate cancer risk variants in men of African ancestry (2015) (60)
Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants (2020) (60)
Common Variants at the 19p13.1 and ZNF365 Loci Are Associated with ER Subtypes of Breast Cancer and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers (2012) (60)
Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy (2019) (60)
Detection of TMPRSS2-ERG translocations in human prostate cancer by expression profiling using GeneChip Human Exon 1.0 ST arrays. (2008) (59)
Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations (2005) (59)
A recurrent truncating germline mutation in the BRIP1/FANCJ gene and susceptibility to prostate cancer (2009) (59)
The potential value of microseminoprotein‐β as a prostate cancer biomarker and therapeutic target (2010) (58)
Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers (2014) (58)
Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers (2014) (58)
Cross Cancer Genomic Investigation of Inflammation Pathway for Five Common Cancers: Lung, Ovary, Prostate, Breast, and Colorectal Cancer. (2015) (57)
p53 therapy in a patient with Li-Fraumeni syndrome (2007) (57)
Association between hormonal genetic polymorphisms and early-onset prostate cancer (2005) (56)
Prediction of individual genetic risk to prostate cancer using a polygenic score (2015) (56)
Blood lipids and prostate cancer: a Mendelian randomization analysis (2016) (55)
Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. (2011) (55)
Whole‐body magnetic resonance imaging in the detection of skeletal metastases in patients with prostate cancer (2009) (55)
A Cross-Cancer Genetic Association Analysis of the DNA Repair and DNA Damage Signaling Pathways for Lung, Ovary, Prostate, Breast, and Colorectal Cancer (2015) (55)
Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers (2019) (55)
A Large-Scale Analysis of Genetic Variants within Putative miRNA Binding Sites in Prostate Cancer. (2015) (54)
Non-Hodgkin's lymphoma presenting with extradural spinal cord compression: functional outcome and survival. (1991) (54)
No evidence for germline mutations in exons 5-9 of the p53 gene in 25 breast cancer families. (1992) (54)
Evaluating Genetic Risk for Prostate Cancer among Japanese and Latinos (2012) (53)
Association of the Variants CASP8 D302H and CASP10 V410I with Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers (2010) (53)
Psychosocial impact of testing (by linkage) for the BRCA1 breast cancer gene: An investigation of two families in the research setting (1996) (53)
BRCA1/2 predictive testing: a study of uptake in two centres (2004) (52)
Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation (2016) (52)
Familial cancer syndromes (1994) (51)
Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia (2018) (50)
A robust method for detecting CHK2/RAD53 mutations in genomic DNA (2002) (49)
The role of genetic factors in predisposition to squamous cell cancer of the head and neck (1999) (49)
Rare germ line CHEK2 variants identified in breast cancer families encode proteins that show impaired activation. (2006) (49)
HPC2/ELAC2 polymorphisms and prostate cancer risk: analysis by age of onset of disease (2002) (47)
Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers (2012) (47)
Polygenic risk-tailored screening for prostate cancer: A benefit–harm and cost-effectiveness modelling study (2019) (47)
“Social Separation” Among Women Under 40 Years of Age Diagnosed with Breast Cancer and Carrying a BRCA1 or BRCA2 Mutation (2006) (47)
Stratified Cancer Screening: The Practicalities of Implementation (2013) (46)
Processing of radical prostatectomy specimens for correlation of data from histopathological, molecular biological, and radiological studies: a new whole organ technique (2005) (46)
Genetic predisposition to prostate cancer (1999) (45)
Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls (2017) (45)
Intensity-modulated radiotherapy allows escalation of the radiation dose to the pelvic lymph nodes in patients with locally advanced prostate cancer: preliminary results of a phase I dose escalation study. (2010) (45)
The genetics of familial breast cancer and their practical implications. (1994) (44)
Polyglutamine repeat length in the AIB1 gene modifies breast cancer susceptibility in BRCA1 carriers (2004) (44)
Biopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillance (2009) (44)
Genetic testing in breast/ovarian cancer (BRCA1) families (1995) (44)
The incidence of breast cancer from screening women according to predicted family history risk: Does annual clinical examination add to mammography? (2001) (43)
Disclosure of Genetics Research Results after the Death of the Patient Participant: A Qualitative Study of the Impact on Relatives (2007) (43)
A patient with 17 primary tumours and a germ line mutation in TP53: tumour induction by adjuvant therapy? (2000) (43)
Clinical implications of family history of prostate cancer and genetic risk single nucleotide polymorphism (SNP) profiles in an active surveillance cohort (2013) (43)
Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. (2011) (42)
Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel (2019) (42)
Salvage radiotherapy in recurrent Hodgkin's disease. (1992) (42)
Healthy women from suspected hereditary breast and ovarian cancer families: the significant others in their lives. (2004) (42)
Sex differences in oncogenic mutational processes (2019) (41)
Integration of multiethnic fine-mapping and genomic annotation to prioritize candidate functional SNPs at prostate cancer susceptibility regions. (2015) (41)
Association between the GCG polymorphism of the selenium dependent GPX1 gene and the risk of young onset prostate cancer (2002) (41)
Immunohistochemical expression of BRCA2 protein and allelic loss at the BRCA2 locus in prostate cancer (1998) (41)
Suggestive evidence for a site specific prostate cancer gene on chromosome 1p36 (2000) (40)
The UK national study of magnetic resonance imaging as a method of screening for breast cancer (MARIBS). (2002) (40)
Accurate Prediction of BRCA1 and BRCA2 Heterozygous Genotype Using Expression Profiling after Induced DNA Damage (2006) (40)
Gene Expression Profiling after Radiation-Induced DNA Damage Is Strongly Predictive of BRCA1 Mutation Carrier Status (2004) (39)
Does genetic counseling have any impact on management of breast cancer risk? (2005) (39)
Familial prostate cancer: the evidence and the Cancer Research Campaign/British Prostate Group (CRC/BPG) UK Familial Prostate Cancer Study. (1997) (39)
Apoptosis, ageing and cancer susceptibility (2003) (39)
Dietary fat and early-onset prostate cancer risk (2010) (38)
Circulating vitamin D concentrations and risk of breast and prostate cancer: a Mendelian randomization study. (2018) (38)
Fine-Mapping the HOXB Region Detects Common Variants Tagging a Rare Coding Allele: Evidence for Synthetic Association in Prostate Cancer (2014) (38)
Construction of tissue microarrays from prostate needle biopsy specimens (2005) (38)
Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial? (2017) (38)
Identification of four new susceptibility loci for testicular germ cell tumour (2015) (38)
Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics. (2007) (37)
Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibility (2007) (37)
Gene promoter hypermethylation in ductal lavage fluid from healthy BRCA gene mutation carriers and mutation-negative controls (2007) (37)
Quantifying the Genetic Correlation between Multiple Cancer Types (2017) (37)
Evaluation of Association of HNF1B Variants with Diverse Cancers: Collaborative Analysis of Data from 19 Genome-Wide Association Studies (2010) (37)
Germline variation at 8q24 and prostate cancer risk in men of European ancestry (2018) (37)
Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer (1999) (36)
Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease (2018) (36)
Common variation in Kallikrein genes KLK5, KLK6, KLK12, and KLK13 and risk of prostate cancer and tumor aggressiveness. (2013) (36)
Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial (2016) (36)
Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort (2016) (36)
Lhermitte's sign as a complication of cisplatin-containing chemotherapy for testicular cancer. (1986) (36)
Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers (2020) (35)
Surveillance and treatment of malignancy in Bloom syndrome. (2008) (35)
Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC (2015) (35)
Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. (2022) (35)
Polygenic hazard score is associated with prostate cancer in multi-ethnic populations (2019) (35)
Telomere structure and maintenance gene variants and risk of five cancer types (2016) (34)
Prostate cancer segregation analyses using 4390 families from UK and Australian population‐based studies (2009) (34)
Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. (2012) (34)
Diagnostic radiation procedures and risk of prostate cancer (2008) (33)
Identification of novel susceptibility loci and genes for prostate cancer risk: A transcriptome-wide association study in over 140,000 European descendants. (2019) (33)
Childhood predictive genetic testing for Li–Fraumeni syndrome (2010) (33)
Integration of ERG gene mapping and gene‐expression profiling identifies distinct categories of human prostate cancer (2009) (33)
Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. (2019) (33)
The role of TP53 in breast cancer development. (1993) (33)
Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study. UK MRI Breast Screening Study Advisory Group. (2000) (33)
Role of Engrailed-2 (EN2) as a prostate cancer detection biomarker in genetically high risk men (2013) (32)
Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility (2017) (32)
Screening for ESR mutations in breast and ovarian cancer patients (1997) (32)
Genotype Phenotype Correlation in Li-Fraumeni Syndrome Kindreds and its Implications for Management (2005) (32)
Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data (2017) (32)
High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriers. (2015) (32)
Genome-wide association of familial prostate cancer cases identifies evidence for a rare segregating haplotype at 8q24.21 (2016) (32)
Germline BRCA 1 mutations increase prostate cancer risk (2015) (31)
BRCA1, BRCA2 and their possible function in DNA damage response (1999) (31)
Germline sequencing DNA repair genes in 5,545 men with aggressive and non-aggressive prostate cancer. (2020) (31)
Multi-stage genome-wide association study identifies new susceptibility locus for testicular germ cell tumour on chromosome 3q25. (2015) (31)
Acute Chemotherapy–Related Toxicity Is Not Increased in BRCA1 and BRCA2 Mutation Carriers Treated for Breast Cancer in the United Kingdom (2006) (31)
Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study (2012) (31)
Phase 1/2 Dose-Escalation Study of the Use of Intensity Modulated Radiation Therapy to Treat the Prostate and Pelvic Nodes in Patients With Prostate Cancer (2017) (31)
Future possibilities in the prevention of breast cancer: Intervention strategies in BRCA1 and BRCA2 mutation carriers (2000) (31)
Increased level of chromosomal damage after irradiation of lymphocytes from BRCA1 mutation carriers (2005) (31)
Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers (2010) (31)
BCL10 is rarely mutated in human prostate carcinoma, small-cell lung cancer, head and neck tumours, renal carcinoma and sarcomas (1999) (30)
Genome-Wide Association Study of Prostate Cancer–Specific Survival (2015) (30)
Progress in prostate cancer (1995) (30)
Genetic Variation in Prostate-Specific Antigen–Detected Prostate Cancer and the Effect of Control Selection on Genetic Association Studies (2014) (30)
Sexual activity and prostate cancer risk in men diagnosed at a younger age (2009) (29)
Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers (2014) (29)
ATM protein overexpression in prostate tumors: possible role in telomere maintenance. (2004) (29)
Expression of Bcl-2, p53, and MDM2 in localized prostate cancer with respect to the outcome of radical radiotherapy dose escalation. (2010) (28)
Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA) (2009) (28)
No germline mutations in the dimerization domain of MXI1 in prostate cancer clusters. The CRC/BPG UK Familial Prostate Cancer Study Collaborators. Cancer Research Campaign/British Prostate Group. (1997) (28)
Rationale for a national multi-centre study of magnetic resonance imaging screening in women at genetic risk of breast cancer. (2000) (28)
Polyunsaturated fatty acids and prostate cancer risk: a Mendelian randomisation analysis from the PRACTICAL consortium (2016) (28)
Predictive testing for germline mutations in the p53 gene: are all the questions answered? (1993) (27)
Is no news good news? Inconclusive genetic test results in BRCA1 and BRCA2 from patients and professionals' perspectives (2010) (27)
Significant Benefits of AIP Testing and Clinical Screening in Familial Isolated and Young-onset Pituitary Tumors (2020) (27)
Chemoprevention options for BRCA1 and BRCA2 mutation carriers. (2000) (27)
The association of germ cell tumours of the testis with sarcoid-like processes. (1992) (27)
The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer (2016) (27)
Association between leptin receptor gene polymorphisms and early‐onset prostate cancer (2003) (27)
DESNT: A Poor Prognosis Category of Human Prostate Cancer. (2017) (27)
Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease (2014) (27)
Mutation analysis of the MSMB gene in familial prostate cancer (2009) (26)
Genome‐wide linkage analysis of 1,233 prostate cancer pedigrees from the International Consortium for prostate cancer Genetics using novel sumLINK and sumLOD analyses (2010) (26)
Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study (2018) (26)
A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data (2019) (26)
Association between polymorphisms of the GPX1 gene and second primary tumours after index squamous cell cancer of the head and neck. (2005) (26)
Assessing the role of insulin‐like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating levels (2016) (26)
A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry. (2020) (26)
A review of targeted screening for prostate cancer: introducing the IMPACT Study (2007) (26)
Allelic imbalance in familial and sporadic prostate cancer at the putative human prostate cancer susceptibility locus, HPC1. CRC/BPG UK Familial Prostate Cancer Study Collaborators. Cancer Research Campaign/British Prostate Group. (1998) (25)
Two-stage Study of Familial Prostate Cancer by Whole-exome Sequencing and Custom Capture Identifies 10 Novel Genes Associated with the Risk of Prostate Cancer. (2020) (25)
An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers (2015) (25)
An integrative multi-omics analysis to identify candidate DNA methylation biomarkers related to prostate cancer risk (2020) (25)
An integrative multi-omics analysis to identify candidate DNA methylation biomarkers related to prostate cancer risk (2020) (25)
Macrophage Scavenger Receptor 1 999C>T (R293X) Mutation and Risk of Prostate Cancer (2005) (25)
Alcohol consumption and prostate cancer incidence and progression: A Mendelian randomisation study (2016) (25)
The psychological impact of undergoing genetic‐risk profiling in men with a family history of prostate cancer (2015) (25)
The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers (2009) (25)
Prophylactic mastectomy for genetic predisposition to breast cancer: the proband's story. (1996) (24)
Men with a susceptibility to prostate cancer and the role of genetic based screening (2018) (24)
Does magnetic resonance imaging of the spine have a role in the staging of prostate cancer? (2009) (24)
A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study (2021) (24)
High risk genes predisposing to prostate cancer development—do they exist? (2000) (24)
Bromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer (2017) (24)
Ductal approaches to assessment and management of women at high risk for developing breast cancer (2004) (23)
Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers (2012) (23)
Homeobox B13 G84E Mutation and Prostate Cancer Risk (2019) (23)
Validation of prostate cancer risk-related loci identified from genome-wide association studies using family-based association analysis: evidence from the International Consortium for Prostate Cancer Genetics (ICPCG) (2012) (23)
Clinical outcome and service implications of screening women at increased breast cancer risk from a family history. (2006) (23)
Glutathione-S-transferase M1, T1 and P1 polymorphisms, and breast cancer risk, in BRCA1/2 mutation carriers (2008) (23)
African‐specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer (2020) (23)
Identification of new genetic risk factors for prostate cancer. (2009) (23)
A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers (2012) (22)
Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up (2013) (22)
Cellular characteristics of nipple aspiration fluid during the menstrual cycle in healthy premenopausal women (2001) (22)
Screening for hereditary cancer and genetic testing, epitomized by breast cancer. (1999) (22)
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (22)
Testing for the breast cancer predisposition gene, BRCA1 (1996) (22)
Combined Effect of a Polygenic Risk Score and Rare Genetic Variants on Prostate Cancer Risk. (2021) (22)
Genetic Testing and Clinical Management Practices for Variants in Non-BRCA1/2 Breast (and Breast/Ovarian) Cancer Susceptibility Genes: An International Survey by the Evidence-Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working Group. (2018) (22)
Optimal age to start preventive measures in women with BRCA1/2 mutations or high familial breast cancer risk (2013) (22)
Feasibility of familial PSA screening: psychosocial issues and screening adherence (2006) (22)
Exploring the link between MORF4L1 and risk of breast cancer (2011) (21)
Primary fibroblasts from BRCA1 heterozygotes display an abnormal G1/S cell cycle checkpoint following UVA irradiation but show normal levels of micronuclei following oxidative stress or mitomycin C treatment. (2004) (21)
Is hormone replacement therapy (HRT) following risk-reducing salpingo-oophorectomy (RRSO) in BRCA1 (B1)- and BRCA2 (B2)-mutation carriers associated with an increased risk of breast cancer? (2011) (20)
The PCR revolution. (1992) (20)
Analysis of Li-Fraumeni syndrome and Li-Fraumeni-like families for germline mutations in Bcl10. (1999) (20)
Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3 (2016) (20)
Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study (2021) (19)
Sweat-gland tumours: a clinical review of cases in one centre over 20 years. (2006) (19)
Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers (2011) (19)
An improved high throughput heteroduplex mutation detection system for screening BRCA2 mutations—fluorescent mutation detection (F‐MD) (2001) (19)
Polymorphisms of an Innate Immune Gene, Toll-Like Receptor 4, and Aggressive Prostate Cancer Risk: A Systematic Review and Meta-Analysis (2014) (19)
A genetic study and meta-analysis of the genetic predisposition of prostate cancer in a Chinese population (2016) (18)
Delivering cancer genetics services-new ways of working (2007) (18)
Carboplatin and etoposide pharmacokinetics in patients with testicular teratoma (2004) (18)
Large-scale Analysis Demonstrates Familial Testicular Cancer to have Polygenic Aetiology. (2018) (18)
Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study (2021) (18)
Genomic analysis of male puberty timing highlights shared genetic basis with hair colour and lifespan (2020) (18)
Proteomic analysis of nipple aspirate fluid throughout the menstrual cycle in healthy pre-menopausal women (2007) (18)
Psychological impact and acceptability of magnetic resonance imaging and X-ray mammography: the MARIBS Study (2011) (18)
Investigating the possible causal role of coffee consumption with prostate cancer risk and progression using Mendelian randomization analysis (2016) (17)
“It’s all very well reading the letters in the genome, but it’s a long way to being able to write”: Men’s interpretations of undergoing genetic profiling to determine future risk of prostate cancer (2014) (17)
Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition (2018) (17)
Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. (2018) (17)
Communicating genetics research results to families: problems arising when the patient participant is deceased (2008) (17)
Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study (2018) (17)
Prostate Cancer Germline Variations and Implications for Screening and Treatment. (2018) (17)
Correction: Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer (2010) (17)
Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder (2015) (17)
Identification of Germline Genetic Variants that Increase Prostate Cancer Risk and Influence Development of Aggressive Disease (2021) (16)
UKCGG Consensus Group guidelines for the management of patients with constitutional TP53 pathogenic variants (2020) (16)
Association study of prostate cancer susceptibility variants with risks of invasive ovarian, breast, and colorectal cancer. (2008) (16)
Corrigendum: Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue (2015) (16)
Identification of shared and unique susceptibility pathways among cancers of the lung, breast, and prostate from genome-wide association studies and tissue-specific protein interactions. (2015) (16)
Multicentric breast cancer: clonality and prognostic studies (2011) (16)
No germline mutations in CDKN2A (p16) in patients with squamous cell cancer of the head and neck and second primary tumours (2001) (16)
Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study (2018) (16)
BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial. (2007) (16)
Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital (2017) (16)
Eligibility for Magnetic Resonance Imaging Screening in the United Kingdom: Effect of Strict Selection Criteria and Anonymous DNA Testing on Breast Cancer Incidence in the MARIBS Study (2009) (16)
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2mutation carriers (2012) (16)
Survival and disease characteristics of de novo versus recurrent metastatic breast cancer in a cohort of young patients (2020) (16)
Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity (2016) (16)
Common Genetic Variation at BARD1 Is Not Associated with Breast Cancer Risk in BRCA1 or BRCA2 Mutation Carriers (2011) (16)
Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer (2021) (16)
Genome-wide association study implicates immune dysfunction in the development of Hodgkin lymphoma. (2018) (16)
Prostate-Specific Antigen in Nipple Aspiration Fluid: Menstrual Cycle Variability and Correlation with Serum Prostate-Specific Antigen (2002) (15)
Association between Prostinogen (KLK15) Genetic Variants and Prostate Cancer Risk and Aggressiveness in Australia and a Meta-Analysis of GWAS Data (2011) (15)
A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers (2021) (15)
Germline genetic variants associated with prostate cancer and potential relevance to clinical practice. (2014) (15)
Reply to “Variation in KLK genes, prostate-specific antigen and risk of prostate cancer” (2008) (15)
Analysis of familial male breast cancer for germline mutations in CHEK2. (2004) (15)
Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers (2019) (15)
Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial (2020) (15)
FRMD6 has tumor suppressor functions in prostate cancer (2020) (15)
The G67E mutation in hMLH1 is associated with an unusual presentation of Lynch syndrome (2009) (15)
Intracardiac metastases from germ cell tumours--an unusual but important site of metastasis. (1992) (15)
Psychosocial effects of whole-body MRI screening in adult high-risk pathogenic TP53 mutation carriers: a case-controlled study (SIGNIFY) (2019) (15)
Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array (2016) (14)
Common Genetic Variants and Modification of Penetrance of BRCA 2-Associated Breast Cancer (2010) (14)
Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2 (2012) (14)
SNP interaction pattern identifier (SIPI): an intensive search for SNP‐SNP interaction patterns (2016) (14)
Proteomics and urine analysis: a potential promising new tool in urology (2004) (14)
Reducing GWAS Complexity (2016) (14)
SNPs in the kallikrein gene region associated with prostate cancer risk: true cause or association by design? (2008) (14)
Lymphocyte Telomere Length Is Long in BRCA1 and BRCA2 Mutation Carriers Regardless of Cancer-Affected Status (2014) (14)
The value of rapid functional assays of germline p53 status in LFS and LFL families (2000) (14)
Germline genetic profiling in prostate cancer: latest developments and potential clinical applications (2015) (14)
Beyond prostate-specific antigen - future biomarkers for the early detection and management of prostate cancer. (2012) (14)
Chromosomes 4 and 8 implicated in a genome wide SNP linkage scan of 762 prostate cancer families collected by the ICPCG (2012) (14)
Prostate cancer screening in BRCA and Lynch syndrome mutation carriers. (2013) (14)
No evidence that GATA3 rs570613 SNP modifies breast cancer risk (2009) (13)
LocusExplorer: a user-friendly tool for integrated visualization of human genetic association data and biological annotations (2015) (13)
Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2 (2011) (13)
Common genetic variants associated with disease from genome-wide association studies are mutually exclusive in prostate cancer and rheumatoid arthritis (2012) (13)
SCREENING FOR PROSTATE CANCER: THE WAY AHEAD (2010) (13)
Oncologically Relevant Findings Reporting and Data System (ONCO-RADS): Guidelines for the Acquisition, Interpretation, and Reporting of Whole-Body MRI for Cancer Screening. (2021) (13)
Outcome of early detection and radiotherapy for occult spinal cord compression. (2007) (13)
HES5 silencing is an early and recurrent change in prostate tumourigenesis (2015) (13)
Analysis of over 140,000 European descendants identifies genetically-predicted blood protein biomarkers associated with prostate cancer risk. (2019) (13)
Patterns of recurrence after prostate bed radiotherapy. (2019) (12)
Polymerase chain reaction (PCR) : the technique and its appplication (1993) (12)
Ploidy and proliferative index in medulloblastoma: useful prognostic factors? (1993) (12)
A Rare Germline HOXB13 Variant Contributes to Risk of Prostate Cancer in Men of African Ancestry (2022) (12)
Genetic predisposition to prostate cancer: an update (2021) (12)
No evidence of germline PTEN mutations in familial prostate cancer (2000) (12)
The effect of sample size on polygenic hazard models for prostate cancer (2019) (12)
Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder (2016) (12)
Genetic predisposition to cancer: the consequences of a delayed diagnosis of Gorlin syndrome. (2005) (12)
The carrier clinic: an evaluation of a novel clinic dedicated to the follow-up of BRCA1 and BRCA2 carriers—implications for oncogenetics practice (2010) (12)
A paradox: urgent BRCA genetic testing (2004) (12)
Translating genetic risk factors for prostate cancer to the clinic: 2013 and beyond. (2014) (12)
The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor (2020) (11)
The BARCODE1 Pilot: a feasibility study of using germline single nucleotide polymorphisms to target prostate cancer screening (2021) (11)
Marital status and prostate cancer incidence: a pooled analysis of 12 case–control studies from the PRACTICAL consortium (2021) (11)
Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci (2019) (11)
Ambiguity in a masculine world: Being a BRCA1/2 mutation carrier and a man with prostate cancer (2017) (11)
Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer (2021) (11)
Dramatic response to platinum in a patient with cancer with a germline BRCA2 mutation. (2009) (11)
Familial prostate cancer and its management (1996) (11)
Prostate cancer meta-analysis from more than 143,000 men identifies 57 novel prostate cancer susceptibility loci (2016) (11)
HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG) (2012) (11)
Apparent Mendelian inheritance of breast and colorectal cancer: chance, genetic heterogeneity or a new gene? (2004) (11)
Unusual presentation of Lynch Syndrome (2009) (11)
The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium (2015) (11)
Loss of Heterozygosity at the BRCA1 and BRCA2 Loci Detected in Ductal Lavage Fluid from BRCA Gene Mutation Carriers and Controls (2006) (11)
National Cancer Institute Prostate Cancer Genetics Workshop. (2011) (11)
An audit of screening for familial breast cancer before 50 years in the South Thames Region – have we got it right? (2004) (10)
Mimics of metastases from testicular tumours. (1990) (10)
Ownership of uncertainty: healthcare professionals counseling and treating women from hereditary breast and ovarian cancer families who receive an inconclusive BRCA1/2 genetic test result. (2011) (10)
Prostate cancer Report of a meeting of physicians and scientists, Institute of Cancer Research and the Royal Marsden Hospital (1993) (10)
Telomere Length Shows No Association with BRCA1 and BRCA2 Mutation Status (2014) (10)
Genetic testing for BRCA1: effects of a randomised study of knowledge provision on interest in testing and long term test uptake; implications for the NICE guidelines (2008) (10)
The utility of digital rectal examination after radical radiotherapy for prostate cancer. (2005) (10)
Germline genetic variation in prostate susceptibility does not predict outcomes in the chemoprevention trials PCPT and SELECT (2019) (10)
Validation of loci at 2q14.2 and 15q21.3 as risk factors for testicular cancer (2017) (10)
Delivery of cancer genetics services: The Royal Marsden telephone clinic model (2007) (10)
Germline mutations in fumarate hydratase (FH) do not predispose to prostate cancer (2003) (10)
Microbiomes of Urine and the Prostate Are Linked to Human Prostate Cancer Risk Groups. (2022) (10)
Correlation of germ-line BRCA2 mutations with aggressive prostate cancer and outcome. (2011) (10)
The predictive ability of the 313 variant–based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant (2021) (10)
Radiotherapy and genetic predisposition to breast cancer. (2006) (9)
Protocol for a national multi-centre study of magnetic resonance imaging screening in women at genetic risk of breast cancer. (2000) (9)
BRCA1/2 carriers and endocrine risk modifiers. (1999) (9)
Functional Analysis Identifies Damaging CHEK2 Missense Variants Associated with Increased Cancer Risk (2021) (9)
Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations (2018) (9)
Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array (2016) (9)
The proteomic approach to urological biomarkers (2004) (9)
Prostate cancer genome-wide association study from 89,000 men using the OncoArray chip to identify novel prostate cancer susceptibility loci. (2016) (9)
Mutations in BRCA1 and BRCA2 and predisposition to prostate cancer (2003) (9)
First international workshop of the ATM and cancer risk group (4-5 December 2019) (2021) (9)
Erratum: Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 (Annals of Oncology (2015) 26(8) (1589–1604), (S0923753419318691), (10.1093/annonc/mdv257)) (2019) (9)
Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores (2021) (9)
Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers (2016) (9)
BARCODE 1: A pilot study investigating the use of genetic profiling to identify men in the general population with the highest risk of prostate cancer to invite for targeted screening. (2020) (9)
gsSKAT: Rapid gene set analysis and multiple testing correction for rare‐variant association studies using weighted linear kernels (2017) (9)
Prostate cancer meta-analysis from more than 145,000 men to identify 65 novel prostate cancer susceptibility loci. (2017) (8)
Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases (2018) (8)
Corrigendum to “Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study” [Eur Urol 2014;66:489–99] (2015) (8)
The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriers. (2015) (8)
Elevated expression of Ki-67 identifies aggressive prostate cancers but does not distinguish BRCA1 or BRCA2 mutation carriers. (2009) (8)
Diffusion-weighted MRI for detecting prostate tumour in men at increased genetic risk (2014) (8)
Exploring the link between MORF4L1 and risk of breast cancer (2011) (8)
Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic TMPRSS2:ERG fusion status (2016) (8)
Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24 (2021) (7)
The accuracy of cancer diagnoses as reported in families with head and neck cancer: a case-control study. (2008) (7)
Genetic Variants in Epigenetic Pathways and Risks of Multiple Cancers in the GAME-ON Consortium (2017) (7)
Diagnosis and Management of Hereditary Carcinoids. (2016) (7)
Analysis of Xq27-28 linkage in the international consortium for prostate cancer genetics (ICPCG) families (2012) (7)
Abstract CT322: DNA repair defects and antitumor activity with PARP inhibition: TOPARP, a phase II trial of olaparib in metastatic castration resistant prostate cancer (2015) (6)
Eligibility for MRI screening in the UK: Effect of strict selection criteria and anonymous DNA testing on breast cancer incidence in the MARIBS study (2009) (6)
The feasibility and results of a population-based approach to evaluating prostate-specific antigen screening for prostate cancer in men with a raised familial risk (2006) (6)
Implications for cancer genetics practice of pro-actively assessing family history in a General Practice cohort in North West London (2012) (6)
Post hoc Analysis for Detecting Individual Rare Variant Risk Associations Using Probit Regression Bayesian Variable Selection Methods in Case‐Control Sequencing Studies (2016) (6)
Corrigendum: Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells. (2016) (6)
Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium (2017) (6)
Genetic testing for cancer predisposition--an ongoing debate. (2000) (6)
The cancer family clinic (1996) (6)
The Clinical Genetics of Prostate Cancer (2004) (6)
Familial breast cancer (1996) (6)
Combining genome-wide studies of breast, prostate, ovarian and endometrial cancers maps cross-cancer susceptibility loci and identifies new genetic associations (2020) (6)
Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score (2021) (6)
Prostate Cancer Risk by BRCA2 Genomic Regions (2020) (5)
Correction: Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer (2010) (5)
Delivering cancer genetics services-new ways of working (2008) (5)
Evidence for SMAD 3 as a modifier of breast cancer risk in BRCA 2 mutation carriers (2010) (5)
Runs of homozygosity and testicular cancer risk (2019) (5)
An Assessment of the Shared Allelic Architecture between Type II Diabetes and Prostate Cancer (2013) (5)
Erratum to: MRI breast screening in high-risk women: cancer detection and survival analysis (2014) (5)
Half of germline pathogenic and likely pathogenic variants found on panel tests do not fulfil NHS testing criteria (2022) (5)
Spontaneous antibodies against Engrailed‐2 (EN2) protein in patients with prostate cancer (2014) (5)
Developments in Clinical Practice: Follow up Clinic for BRCA Mutation Carriers: a Case Study Highlighting the "Virtual Clinic" (2004) (5)
Screening for ovarian cancer in women with varying levels of risk, using annual tests, results in high recall for repeat screening tests (2011) (5)
Large-scale cross-cancer fine-mapping of the 5p15.33 region reveals multiple independent signals (2021) (5)
Supplementary file 1. (2015) (4)
Publisher Correction: Shared heritability and functional enrichment across six solid cancers (2019) (4)
Abstract 5065: Fine-mapping theHOXBregion detects common variants tagging a rare coding allele: Evidence for synthetic association in prostate cancer (2014) (4)
Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma (2019) (4)
KLK3 SNP–SNP interactions for prediction of prostate cancer aggressiveness (2021) (4)
Prostate cancer risk in men of differing genetic ancestry and approaches to disease screening and management in these groups (2021) (4)
What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021 (2022) (4)
Baseline and post prophylactic tubal–ovarian surgery CA125 levels in BRCA1 and BRCA2 mutation carriers (2014) (4)
Updates in Prostate Cancer Research and Screening in Men at Genetically Higher Risk (2021) (4)
Germline and somatic studies in the TP53 gene in breast and other cancers. (2000) (4)
Supplementary file 3. (2014) (4)
Effect of germ-line BRCA mutations in biochemical relapse and survival after treatment for localized prostate cancer. (2013) (4)
A genetic risk score to guide age-specific, personalized prostate cancer screening (2016) (3)
Use of a Novel Nonparametric Version of DEPTH to Identify Genomic Regions Associated with Prostate Cancer Risk (2016) (3)
Overexpression of TP53 is Associated with Aggressive Prostate Cancer butdoes not Distinguish Disease in BRCA1 or BRCA2 Mutation Carriers froma Control Group (2009) (3)
The Identification of Rare and Common Variants Which Predispose to Prostate Cancer (2010) (3)
A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer (2021) (3)
AA9int: SNP interaction pattern search using non‐hierarchical additive model set (2018) (3)
Correction: Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease (2018) (3)
seXY: a tool for sex inference from genotype arrays (2016) (3)
Abstract 1301: Identification of novel susceptibility loci and genes for prostate cancer risk: A large transcriptome-wide association study in over 143,000 subjects (2017) (3)
Risk Analysis of Prostate Cancer in PRACTICAL Consortium—Response (2016) (3)
p 53 therapy in a patient with Li-Fraumeni syndrome (2007) (3)
Management of a woman with a family history of breast cancer (2006) (3)
DNA repair gene panel mutations in young onset prostate cancer cases in the. (2018) (3)
Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction (2021) (3)
Abstract 2546: Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates withTERTexpression. (2013) (3)
Phase III trial of conformal radiotherapy following neoadjuvant hormone treatment in early prostate cancer (2002) (3)
Author Correction: Germline variation at 8q24 and prostate cancer risk in men of European ancestry (2019) (3)
AIDIT and IMPACT: building research collaborations in targeted prostate cancer screening. (2006) (2)
Forum for Applied Cancer Education and Training (FACET). (2002) (2)
Cancer genes – Management of carriers of breast cancer genes who have already developed cancer: the Carrier Clinic Model (2002) (2)
Author Correction: Large-scale transcriptome-wide association study identifies new prostate cancer risk regions (2019) (2)
Family History of Prostate Cancer and Survival Outcomes in the UK Genetic Prostate Cancer Study. (2022) (2)
Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium (2017) (2)
Non-uptake of predictive genetic testing for BR-CA1/2: attributes, cancer worry and barriers to testing in a multi-centre clinical cohort (2003) (2)
BRCA1, BRCA2 and pedigree genetic analysis to determine genetic risk in the UK Royal Marsden Hospital tamoxifen prevention trial (2000) (2)
Bilateral prophylactic mastectomy: not just a woman's problem! (1998) (2)
Optimizing the diagnosis of prostate cancer in high‐risk men: the supplementary biomarker approach (2005) (2)
HOXB13 G84E Mutation and Prostate Cancer Risk: Kin-Cohort Analysis Using Data From the UK Genetic Prostate Cancer Study (2017) (2)
Author Correction: The evolutionary history of lethal metastatic prostate cancer (2020) (2)
Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition (2018) (2)
Abstract PO-146: Multiethnic GWAS meta-analysis identifies novel variants and informs genetic risk prediction for prostate cancer across populations (2020) (2)
Whole body screening , TP 53 mutation carriers , psychosocial morbidity Psychosocial morbidity in TP 53 mutation carriers – is whole-body cancer screening beneficial ? (2016) (2)
Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction (2021) (2)
Abstract 2565: Prostate cancer GWAS from more than 89,000 men identifies more than 30 novel prostate cancer susceptibility loci (2016) (2)
IDENTIFICATION OF MEN WITH A GENETIC PREDISPOSITION TO PROSTATE CANCER: TARGETED SCREENING OF BRCA1 AND BRCA2 MUTATION CARRIERS AND CONTROLS THE IMPACT STUDY PILOT RESULTS (2009) (2)
Supplementary file 2. (2014) (2)
RAZOR: A Phase II Open Randomized Trial of Screening Plus Goserelin and Raloxifene Versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer (2017) (2)
Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases (2018) (1)
CanRisk-Prostate: A Comprehensive, Externally Validated Risk Model for the Prediction of Future Prostate Cancer (2022) (1)
Loco-regional treatment (LRT) for M1 at diagnosis prostate cancer (PCa) patients (pts) and impact on overall survival (OS): A retrospective analysis. (2016) (1)
Acne and Prostate Cancer Risk. (2014) (1)
A population-based audit of ethnicity and breast cancer risk in one general practice catchment area in North London, UK: implications for practice (2007) (1)
Identi fi cation of shared and unique susceptibility pathways among cancers of the lung , breast , and prostate from genome-wide association studies and tissue-speci fi c protein interactions (2015) (1)
Survival and disease characteristics of de novo versus recurrent metastatic breast cancer in a cohort of young patients (2020) (1)
phylogenetic approach identified mitochondrial haplogroup T 1 a 1 as inversely associated with breast cancer risk in BRCA 2 mutation carriers (2015) (1)
UK National Trial assessing the impact of testing for BRCA1/2 breast/ovarian cancer predisposition genes (1998) (1)
Abstract P1-09-05: The RAZOR trial: a phase II prevention trial of screening plus goserilin and raloxifene versus screening alone in pre-menopausal women at increased risk of breast cancer. (2012) (1)
Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in $\small \textit{BRCA1}$ and $\small \textit{BRCA2}$ Mutation Carriers (2016) (1)
The New Genomics Era: Integration of genomics into mainstream oncology and implications for psycho‐oncological care (2020) (1)
Bromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer (2017) (1)
Alcohol Intake and Alcohol–SNP Interactions Associated with Prostate Cancer Aggressiveness (2021) (1)
Effects of BRCA2 cis-regulation in normal breast and cancer risk amongst BRCA2 mutation carriers (2012) (1)
Null Results in Brief Common Genetic Variation at BARD 1 Is Not Associated with Breast Cancer Risk in BRCA 1 or BRCA 2 Mutation Carriers (2011) (1)
The BARCODE1 study in primary care: Early results targeting men with increased genetic risk of developing prostate cancer—Examining the interim data from a community-based screening program using polygenic risk score to target screening. (2022) (1)
Implications for cancer genetics practice of pro-actively assessing family history in a General Practice cohort in North West London (2011) (1)
Abstract 2174: Identification of genetic factors contributing to development of common cancers through tissue-specific protein interaction analysis (2015) (1)
Upfront Docetaxel in the Post-STAMPEDE World: Lessons from an Early Evaluation of Non-trial Usage in Hormone-Sensitive Prostate Cancer. (2017) (1)
Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants (2018) (1)
Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers (2020) (1)
Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers (2020) (1)
Coffee Intake, Caffeine Metabolism Genotype, and Survival Among Men with Prostate Cancer. (2022) (1)
Erratum: Selective organ preservation with neo-adjuvant chemotherapy for the treatment of muscle invasive transitional cell carcinoma of the bladder (British Journal of Cancer (2015) 112, (1626-1635)) doi: 10.1038/bjc.2015.109 (2016) (1)
Cervical Spine Fractures in Patients Undergoing Palliative Radiotherapy to the Cervical Spine: Implications for Practice. (2018) (1)
Abstract 1650: Overview of the clinical ELLIPSE (ELucidating Loci Involved in Prostate cancer SuscEptibility) Consortium (CEC) (2012) (1)
Uterine cancer (Ut Ca) following risk-reducing salpingo-oophorectomy (RRSO) in women with BRCA mutations (BRCA+): A multicenter, prospective study. (2015) (1)
Supplementary File 4 (2014) (1)
The incidence of germline p53 mutations in 53 Li-Fraumeni-like families and in individuals with multiple primary tumors (1994) (1)
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. (2022) (1)
Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia (2018) (1)
Author Correction: Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility (2019) (1)
Erratum: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: An international prospective cohort of BRCA1 and BRCA2 mutation carriers (Breast Cancer Res (2020) 22 (8) DOI: 10.1186/s13058-020-1247-4) (2020) (1)
Genetics of prostate cancer and its utility in treatment and screening. (2021) (1)
The meaning of risk: Women's perceptions of the genetic risk of breast and ovarian cancer following BRCA1/2 mutation searching (2002) (1)
Additional SNPs improve the performance of a polygenic hazard score for prostate cancer (2020) (1)
Breast cancer screening (2007) (1)
Abstract 1225: Rare variants in DNA damage repair genes are associated with male breast cancer predisposition (2018) (1)
Targeted Screening in Men with a Genetic Predisposition to Prostate Cancer. The IMPACT Study (2007) (1)
Prostate Cancer UK: the Blue Skies Forum (2013) (1)
Title Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA 1 and BRCA 2 mutation carriers (2015) (1)
Genetic Risk Prediction for Prostate Cancer: Implications for Early Detection and Prevention. (2023) (1)
Short report. The AIDIT and IMPACT conference 2006: Outcomes and future directions (2007) (1)
Simultaneous breast cancer in non-identical Ashkenazi Jewish twins: management dilemmas when genetic testing is negative. (2000) (1)
Influence of cytokine polymorphisms on susceptibility to and/or prognosis in prostate cancer (2002) (1)
Author Correction: Pan-cancer analysis of whole genomes (2023) (1)
Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer—Prevalence and Current Clinical Practice (2022) (1)
Accurate Prediction of BRCA 1 and BRCA 2 Heterozygous Genotype Using Expression Profiling after Induced DNADamage (2006) (1)
497 oral PHASE III PILOT STUDY OF DOSE ESCALATION USING CON-FORMAL RADIOTHERAPY IN PROSTATE CANCER: LONG TERM FOLLOW UP (2011) (1)
Abstract 4340: DNA repair genes aberrations in germline DNA in metastatic castration-resistant prostate cancer patients (2016) (1)
Validation of prostate cancer risk-related loci identified from genome-wide association studies using family-based association analysis: evidence from the International Consortium for Prostate Cancer Genetics (ICPCG) (2011) (1)
Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers to detect clinically significant disease: Results from the initial screening round of the IMPACT study. (2014) (1)
Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma (2018) (1)
Breast Cancer Risk and 6 q 22 . 33 : Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA 1 / 2 (2012) (1)
Clonal hematopoiesis and risk of prostate cancer in large samples of European ancestry men. (2022) (1)
Accurate prediction of BRCA1 and BRCA2 heterozygous genotypes using expression profiling of lymphocytes after irradiation-induced DNA damage (2008) (1)
Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical Prostate Cancer Treatment: A Pan Prostate Cancer Group Study. (2022) (1)
Evaluating Germline Testing Panels in Southern African Males With Advanced Prostate Cancer. (2023) (1)
IMPACT Study: Targeted Prostate Cancer Screening. (2013) (1)
Pubertal development and prostate cancer risk (2018) (1)
The genetics of inherited cancers (2020) (0)
Serum testosterone and prostate cancer in men with germline BRCA1/2 pathogenic variants (2023) (0)
Alcohol consumption and prostate cancer incidence and progression: A Mendelian randomisation study. (1), (2016) (0)
Age distribution and a multi-stage theory of carcinogenesis: 70 years on (2022) (0)
Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia | NOVA. The University of Newcastle's Digital Repository (2014) (0)
P2-250 Omega 3 polyunsaturated fatty acids (PUFAs) and risk of early onset prostate cancer (2011) (0)
PD64-11 THE PRACTICAL POLYGENIC RISK SCORE IS ASSOCIATED WITH PROSTATE CANCER MORTALITY INDEPENDENT OF PSA BUT HAS LOW PREDICTIVE VALUE (2019) (0)
Author Correction: Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia (2019) (0)
Cross-cancer genome-wide association analysis of lung, ovary, breast, prostate and colon cancer identifies a novel cancer locus at 1q22 (2015) (0)
Abstract 2415: Polygenic risk-tailored screening for prostate cancer: A cost-effectiveness analysis (2019) (0)
ociation of the Variants CASP 8 D 302 H and CASP 10 0 I with Breast and Ovarian Cancer Risk in B & P A 1 and BRCA 2 Mutation Carriers (2010) (0)
The British Prostate Group Autumn Meeting, 10–11 September 2001, Royal College of Surgeons, Lincoln's Inn Fields, London, UK (2002) (0)
Abstract 956: The evolutionary history of lethal metastatic prostate cancer (2015) (0)
Ageing & cancer susceptibility: Is systemic failure of apoptosis a factor? (2002) (0)
Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia (2014) (0)
“It’s all very well reading the letters in the genome, but it’s a long way to being able to write”: Men’s interpretations of undergoing genetic profiling to determine future risk of prostate cancer (2014) (0)
Rare DNA repair gene mutations predispose to young onset and lethal prostate cancer in the UK (2017) (0)
O-58 The UK MARIBS study of MRI breast screening: progress on genetic and density projects (2007) (0)
2574 Prostate-Specific Antigen velocity as a predictive biomarker in a prospective prostate cancer screening study of men with genetic predisposition (2015) (0)
Short Report The Utility of Digital Rectal Examination after Radical Radiotherapy for Prostate Cancer (2005) (0)
IMPACT and AIDIT: Strengthening Research Ties in Eastern Europe (2006) (0)
MP63-15 THE PROFILE FEASIBILITY STUDY: GENETIC PROSTATE CANCER RISK STRATIFICATION FOR TARGETED SCREENING (2014) (0)
On Adjuvant Hormone Therapy in Epithelial Ovarian Cancer Reply (2016) (0)
Abstract 1296: Bayesian fine-mapping using summary data of 145,000 subjects refines common risk associations, discovers secondary signals and novel candidate genes for prostate cancer (2017) (0)
Validation of the biopsy tissue microarray technique using Ki-67 expression in untreated localized prostate cancer managed by active surveillance. (2008) (0)
Abstract 2969: Genetically predicted blood protein biomarkers and prostate cancer risk: an analysis in over 140,000 European descendants (2018) (0)
Profile study: Genetic prostate cancer risk stratification for targeted screening. (2013) (0)
Abstract 262: The PROFILE feasibility study: Genetic prostate cancer risk stratification for targeted screening (2014) (0)
MP07-05 SERUM TESTOSTERONE AS A BIOMARKER FOR PROSTATE CANCER DIAGNOSIS IN THE IMPACT POPULATION (2016) (0)
Short Report Investigating the possible causal role of coffee consumption with prostate cancer risk and progression using Mendelian randomization analysis (2019) (0)
Correction: Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease (2019) (0)
Hereditary cancer. (2000) (0)
Corrigendum to “What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021” [Eur Urol 82(1):6–11] (2022) (0)
26INGENETIC RISK AND ITS IMPLICATIONS FOR CANCER SURVEILLANCE. (2014) (0)
Abstract 4495: Clinical implications of family history of prostate cancer in an active surveillance cohort (2012) (0)
Erratum: Correction to: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers (Breast cancer research : BCR (2020) 22 1 (8)) (2020) (0)
Abstract 4612: Genetic variants in epigenetic pathways and risk of multiple cancer types in the GAME-ON consortium (2015) (0)
The Prostate 70 : 333 ^ 340 ( 2010 ) The Potential Value ofMicroseminoprotein-b as a ProstateCancerBiomarker andTherapeuticTarget (2010) (0)
Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (0)
Abstract 1311: Germline variation at 8q24 and prostate cancer risk (2017) (0)
NIHMS662581-supplement-Supplementary data (2016) (0)
Risk profiling for cancer prevention and screening – lessons for the future (2018) (0)
Chromosome radiosensitivity and apoptosis in breast cancer susceptibility. (2005) (0)
Author Correction: The evolutionary history of 2,658 cancers (2023) (0)
4 The genetics of prostate cancer (1995) (0)
Correction to: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers (2020) (0)
Radiosensitivity in breast cancer susceptibility. (2005) (0)
Clinical Cancer Genetics (2020) (0)
Edinburgh Research Explorer Unusual presentation of Lynch Syndrome (2009) (0)
Abstract 4836: Gene and environment interactions of height and selected candidate SNPs in prostate cancer: results from the PRACTICAL consortium. (2013) (0)
Prostate Cancer DESNT : A Poor Prognosis Category of Human Prostate Cancer (2017) (0)
2 Familial Prostate Cancer (2005) (0)
Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers (2014) (0)
CARBOPLATIN DOSE DETERMINATION USING A SIMPLE FORMULA - SINGLE AGENT, COMBINATION AND HIGH-DOSE STUDIES (1989) (0)
MP86-11 PROSTATE SPECIFIC ANTIGEN VELOCITY AS A PREDICTIVE BIOMARKER IN A PROSPECTIVE PROSTATE CANCER SCREENING STUDY OF MEN WITH GENETIC PREDISPOSITION (2015) (0)
Author Correction: Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility (2019) (0)
moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients, British Journal of Cancer, Vol. 105(8), 1230-1234 BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in p (2015) (0)
BRCA carrier status as an independent prognostic factor associated with earlier biochemical relapse in local prostate cancer. (2012) (0)
SHORT REPORT Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibility (2007) (0)
Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease (2018) (0)
Primary fibroblasts from BRCA1 mutation-carrying members of breast cancer families display a G1/S cell cycle checkpoint defect following UVA irradiation but show normal levels of micronuclei following oxidative stress or mitomycin C treatment. (2004) (0)
of sample on polygenic hazard models for prostate cancer. (2020) (0)
Reply to S. Kilickap et al, Y. Karakas et al, and I.A. Voutsadakis. (2016) (0)
The profile study: Prostate cancer screening in men of Black African and African Caribbean ancestry—Early results. (2023) (0)
Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition (vol 118, pg 266, 2018) (2018) (0)
Genome-wide association of familial prostate cancer cases identifies evidence for a rare segregating haplotype at 8q24.21 (2016) (0)
Abstract 3638: Detecting prostate cancer in BRCA1 and BRCA2 mutation carriers: A role for EN2 (2012) (0)
Abstract 4606: Fine mapping of 64 prostate cancer GWAS regions identifies multiple novel association signals (2015) (0)
Abstract 5742: Hand pattern and prostate cancer risk (2010) (0)
radiological studies : a new whole molecularcorrelation of data from histopathological , Processing of radical prostatectomy specimens for (2005) (0)
Predictive genetic testing for BRCA1/2 in the UK: The long-term psychosocial impact (2004) (0)
Disseminating BRCA2 test results identified in the research context to relatives of deceased prostate cancer patients: A qualitative study of relatives' experiences (2006) (0)
12: Proffered Paper: The life history of lethal metastatic prostate cancer (The UK prostate cancer working group of the International Cancer Genome Consortium) (2014) (0)
Prostate cancer patients with BRCA2 mutations require urgent treatment (2013) (0)
Author Correction: Patterns of somatic structural variation in human cancer genomes (2020) (0)
Abstract NG03: Multiethnic prostate cancer GWAS meta-analysis identifies novel variants, improves genetic risk prediction across populations, and informs biological mechanisms of prostate cancer (2021) (0)
PLOS ONE Polymorphisms of an Innate Immune Gene, Toll-Like Receptor 4, and Aggressive Prostate Cancer Risk: A Systematic Review and Meta-analysis (2014) (0)
Hereditary predisposition and gene discovery (1996) (0)
Male breast cancer in BRCA1 and BRCA2 mutation carriers (2018) (0)
University of Groningen DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers Osorio, (2014) (0)
University of Groningen Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk Couch, (2013) (0)
BRCA1 and BRCA2: breaking the cycle and repairing the damage (2004) (0)
Title Interplay between BRCA 1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer (2012) (0)
Spatio-genomic heterogeneity within localized, multi-focal prostate cancer (2015) (0)
Abstract 4249: High-Frequency of TMPRSS2-ERG fusion gene identifies a non-random androgen-driven event of chromosomal instability in BRCA mutated prostate cancer (2015) (0)
Comments and Critique Predictive Testing for Germline Mutations in the ~53 Gene: Are All the Questions Answered? (1993) (0)
Hand pattern and early-onset prostate cancer risk (2010) (0)
Author Correction: Large-scale transcriptome-wide association study identifies new prostate cancer risk regions (2019) (0)
Germline sequencing of advanced prostate cancer patients in the BARCODE2 trial (2019) (0)
Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer (2021) (0)
Abstract 5066: Generalizability of established prostate cancer risk variants in men of African ancestry (2014) (0)
Abstract 642: Body fat distribution and prostate cancer risk: A UK case-control study (2012) (0)
Attitudes towards reproductive options for childless individuals following a breast/ovarian cancer gene mutation test (2013) (0)
Abstract P4-11-05: Optimal age to start preventive measures in women with BRCA1/2 mutations or high familial breast cancer risk (2012) (0)
First international workshop of the ATM and cancer risk group (4-5 December 2019) (2021) (0)
Baseline and post prophylactic tubal–ovarian surgery CA125 levels in BRCA1 and BRCA2 mutation carriers (2014) (0)
Large-scale transcriptome-wide association study identifies new prostate cancer risk regions (2018) (0)
The impact of ‘uninformative’ BRCA1/2 genetic test results on health professionals, caring for affected and unaffected women with a significant breast cancer family history (2009) (0)
Impact of predictive genetic testing for BRCA 1/2 in a clinical cohort: three years on (2005) (0)
PD65-04 THE PROFILE STUDY. TARGETED SCREENING USING GERMLINE GENETICS IN MEN WITH A FAMILY HISTORY OF PROSTATE CANCER (2021) (0)
Risk Prediction in Breast Cancer (2007) (0)
Dilemmas encountered when talking about BRCA1/2 testing (2005) (0)
Disclosure of genetics research results after the death of the proband: A qualitative study of the impact on relatives (2007) (0)
Abstract 3810: BRCA2 is a moderate penetrance gene contributing to young onset prostate cancer, but not disease over 65 years (2011) (0)
An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers (2015) (0)
association studies cancer and the effect of control selection on genetic Genetic variation in protein specific antigen detected prostate (2014) (0)
The genetics of breast cancer (2002) (0)
Genomic analysis of male puberty timing highlights shared genetic basis with hair colour and lifespan (2020) (0)
The PROFILE study. Targeted screening using germline genetics in men with a family history of prostate cancer (2021) (0)
Abstract 3862: Identification of a novel genetic variant in theKLK3gene which predisposes to prostate cancer (2010) (0)
Whole genome germline sequencing: Its role in general health screening in family practice, the first study in the UK. (2022) (0)
The genetics of prostate cancer (2014) (0)
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci (2018) (0)
Implementing molecular characterisation of prostate cancer tissue from patients recruited to the multi-centre STAMPEDE trial: The STRATOSPHERE consortium. (2018) (0)
Genetic predisposition to prostate cancer: an update (2021) (0)
Familial prostate cancer (2020) (0)
Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study (2018) (0)
Baseline screening and psychosocial results from the UK SIGNIFY study: A whole-body MRI screening study in TP53 mutation carriers and matched controls. (2017) (0)
The forgotten index case: Recruitment problems in the context of familial prostate screening in a research programme [Abstract] (2006) (0)
q 31 . 2 and in ZNF 365 are associated with breast cancer risk for BRCA 1 and / or BRCA 2 mutation carriers (2012) (0)
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. (2019) (0)
Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility (2017) (0)
Management of Breast Cancer in BRCA1/2 Mutation Carriers (2002) (0)
Abstract 2612: The PROFILE study; Germline genetic profiling: Correlation with targeted prostate cancer screening and treatment (2012) (0)
Germline genetic variation in prostate susceptibility does not predict outcomes in the chemoprevention trials PCPT and SELECT (2019) (0)
The role of DNA repair in radiotherapy. (2000) (0)
ThePROFILEFeasibilityStudy:TargetedScreeningofMenWithaFamily History of Prostate Cancer (2016) (0)
Pre-Symptomatic testing for breast and ovarian cancer predisposition genes: Results from the UK National Cohort Study. (2002) (0)
Heredity and cancer. (1972) (0)
The effect of sample size on polygenic hazard models for prostate cancer (2020) (0)
Fine-mapping identifies multiple prostate cancer risk loci on 5p15 some associating with TERT expression (2013) (0)
786PDDNA repair gene panel mutations in young onset and aggressive vs non aggressive prostate cancer cases in the UK (2017) (0)
Detecting prostate cancer in BRCA1 and BRCA2 mutation carriers: A role for EN2? (2012) (0)
Prognostic factors for survival of patients with sarcoma (1993) (0)
A Comparison of the Biodiversities of 'Lakes' A to D and Lakes E and F (2005) (0)
Author Correction: Germline variation at 8q24 and prostate cancer risk in men of European ancestry (2019) (0)
Tubio retrotransposition in cancer genomes Extensive transduction of nonrepetitive DNA mediated by L 1 (2014) (0)
PRACTICAL (2016). Blood lipids and prostate cancer: a Mendelian randomization analysis. (2016) (0)
Analysis techniques in the presence of non-proportional hazards (PH); application to an ovarian cancer RCT with long-term follow-up (2015) (0)
Financial Restraint and Special Education in British Columbia. (1982) (0)
Genome-Wide LinkageAnalysis of 1 , 233 Prostate Cancer Pedigrees Fromthe International Consortium for ProstateCancerGeneticsUsingNovel sumLINKandsumLODAnalyses (2010) (0)
Clinical implications of a prostate cancer risk SNP profile in two treatment cohorts. (2013) (0)
Circulating vitamin D and risk of breast and prostate cancer: a Mendelian randomization study (2018) (0)
Genetic pre-disposition and enviromental influences on the genesis of prostate cancer. (2005) (0)
Association analyses identify 31 new risk loci for colorectal cancer susceptibility (2019) (0)
Front & Back Matter (2013) (0)
Association analysis of 9,560 prostate cancer cases from the International Consortium of Prostate Cancer Genetics confirms the role of reported prostate cancer associated SNPs for familial disease (2013) (0)
The BARCODE1 pilot study targeting men with increased genetic risk of developing prostate cancer: Examining the feasibility of a community-based screening program using polygenic risk score to target screening. (2021) (0)
Correction to: Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers (2020) (0)
PD-0298: IMPACT study - Targeted prostate cancer screening for rare germline mutation carriers (2014) (0)
Germline variation at 8q24 and prostate cancer risk in men of European ancestry (2018) (0)
Abstract 4577: Identification of twenty three novel prostate cancer susceptibility loci using a custom assay (the icogs) in an international consortium: PRACTICAL. (2013) (0)
The PROFILE feasibility study: Genetic prostate cancer risk stratification for targeted screening. (2014) (0)
A GWAS identified functional variation in PSA (KLK3) gene that confers lower risk is also associated with more aggressive disease and lower survival in men with prostate cancer (2019) (0)
SNP rs2180341 per-allele hazard ratios (HRs) and 95% confidence intervals (CIs) among Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) in A. BRCA1 mutation carriers B. BRCA2 mutation carriers. (2012) (0)
Supplementary file 5. (2014) (0)
Germline sequencing of advanced prostate cancer patients in the BARCODE2 study. (2018) (0)
Blood lipids and prostate cancer: a Mendelian randomization analysis PRACTICAL consortium (2020) (0)
1 Title : Post-hoc Analysis for Detecting Individual Rare Variant Risk Associations using Probit Regression Bayesian Variable Selection Methods in Case-Control Sequencing Studies Running Title : Bayesian Probit Rare Variant Analysis (2017) (0)
Family communication about genetics research results identified following the death of a relative: How information is conveyed and perceived (2007) (0)
Longer Telomere length associates with Prostate Cancer (2014) (0)
Shared heritability and functional enrichment across six solid cancers (2019) (0)
Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial? (2017) (0)
Supplementary file 6. (2014) (0)
The architecture of clonal expansions in morphologically normal tissue from cancerous and non-cancerous prostates (2022) (0)
Assessing the Incidence of Bowel Incontinence in Patients with Urological Cancers Who Have and Have Not Received Pelvic Radiotherapy using the Vaizey and RTOG: Interim Results (2006) (0)
MP05-07 THE PROFILE STUDY—TARGETED SCREENING USING GERMLINE GENETICS IN MEN WITH A FAMILY HISTORY OF PROSTATE CANCER: THE ROLE OF MULTIPARAMETRIC MRI (2021) (0)
The use of germline genetic markers in the androgen receptor gene to identify individuals at increased risk of prostate cancer relapse (1998) (0)
OC-0447: Stereotactic Body Radiotherapy (SBRT) in oligometastatic prostate cancer patients (2016) (0)
Abstract 4681: Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish arm of the European randomised study of screening for prostate cancer (ERSPC) (2015) (0)
Abstract LB011: Meta-analysis in more than 80,000 men of African ancestry identified nine novel variants associated with prostate cancer (2021) (0)
Abstract 688: Multi-stage exome sequencing study of 17,546 aggressive and non-aggressive prostate cancer cases (2022) (0)
P386: Screening for endometrial cancer in a high‐risk population (Hereditary Non Polyposis Colorectal Cancer)—a pilot study (2003) (0)
Developments in the study of familial breast cancer. (1995) (0)
Author Correction: Inferring structural variant cancer cell fraction (2022) (0)
Relationship of self-reported body size and shape with risk for prostate cancer: A UK case-control study (2020) (0)
Cancer prevention and screening (2018) (0)
SP-0290: The issue of the quality of data in biobanking (2015) (0)
Author Correction: Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia (2019) (0)
Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction (2021) (0)
Abstract 1818: Identification of men with a genetic predisposition to prostate cancer: Targeted screening ofBRCA1/2mutation carriers and controls; The IMPACT study (2011) (0)
Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls (2017) (0)
Abstract SY32-02: Genetic predisposition to prostate cancer (PrCa) and its clinical application (2014) (0)
Prostate-specific antigen velocity as a predictive biomarker in a prospective prostate cancer screening study (IMPACT study). (2015) (0)
Reply: ‘Hand pattern indicates risk of prostate cancer’ (2011) (0)
Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes (2020) (0)
Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2 (2016) (0)
Session 5 Primary prevention of breast cancer I: Ovarian suppression and ablation in premenopausal women at risk (2004) (0)
How can we recruit more men of African or African-Caribbean ancestry into our research? Co-creating a video to raise awareness of prostate cancer risk and the PROFILE study (2022) (0)
Association of the prostate cancer risk mutation G84E in HOXB13 with the subtype of ETS fusion negative adenocarcinoma with early age of diagnosis. (2015) (0)
A genetic hazard score to personalize prostate cancer screening, applied to population data (2019) (0)
Genome analysis AA 9 int : SNP Interaction Pattern Search Using Non-Hierarchical Additive Model Set (2018) (0)
Urgent genetic testing - a paradox? (2001) (0)
No evidence of germline CDKN2A mutations in multiple primary tumours of the head and neck (1999) (0)
751OPREVALENCE OF HOXB13G84E GERMLINE MUTATION IN UK PROSTATE CANCER CASES; CORRELATION WITH TUMOUR CHARACTERISTICS AND OUTCOMES. (2014) (0)
Genetics - where are we? (2004) (0)
Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma (2019) (0)
Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci (2019) (0)
Antitumour Activity of the Poly(Adp-Ribose) Polymerase (Parp) Inhibitor Olaparib in Unselected Sporadic Castration Resistant Prostate Cancer (Crpc) in the Toparp Trial (2015) (0)
HNPCC - Where does the buck stop? (2004) (0)
The Genetics Feature Article of Familial Breast Cancer and Their Practical Implications (1994) (0)
OP-JNCI190078 1..12 (2019) (0)
GENOME-WIDE ASSOCIATION STUDY OF HODGKIN LYMPHOMA IDENTIFIES HISTOLOGY-SPECIFIC ASSOCIATIONS AND TRANSCRIPTIONAL REGULATORS OF DISEASE SUSCEPTIBILITY (2017) (0)
Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer (2019) (0)
Overexpression of TP 53 is Associated with Aggressive Prostate Cancer but does not Distinguish Disease in BRCA 1 or BRCA 2 Mutation Carriers from a Control Group (2009) (0)
Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets (2018) (0)

This paper list is powered by the following services:

Other Resources About Rosalind Eeles

en.wikipedia.org

What Schools Are Affiliated With Rosalind Eeles?

Rosalind Eeles is affiliated with the following schools: